Pfizer Inc. subsidiary Wyeth pled guilty to off-label marketing of the immunosuppressive drug Rapamune (sirolimus) and agreed to pay $490.9 million to resolve criminal and civil liability.
Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA
Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.
More from United States
• By
The preliminary budget document supports legislation clawing back funds appropriated for the program.
• By
Lowell Zeta, a senior counselor at the FDA from 2020 to 2021, returns as deputy commissioner for strategic initiatives. The agency also names a new acting CIO and acting CVM director, but OGD's Ted Sherwood and OPDP's Catherine Gray retired.
• By
The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.
• By
US CDC’s Advisory Committee on Immunization Practices voted for harmonized meningococcal vaccine recommendations, while hearing updates about Sanofi’s pending supplemental MedQuadfi indication, AstraZeneca’s FluMist self-administration launch plans, and Lyme disease
More from North America
• By
Ascertaining the novelty and benefits of Makary’s new drug approval idea – along with what it would take to implement it – requires more clarity on the types of studies he envisions being used to grant and confirm “plausible mechanism’ approvals.
• By
Consumer and academic group comments on accelerated approval and confirmatory trial guidances say the proposed criteria for determining when a study is underway are too vague.
• By
Bavarian Nordic's Vimkunya added the US CDC immunization committee's recommendation to its FDA approval, while Valneva's Ixchiq faces a precaution for use in people aged 65 and older.